• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Actelion shareholders OK R&D spinout

April 5, 2017 By Sarah Faulkner

Actelion shareholders OK R&D spinoutActelion (VTX:ATLN) shareholders today reportedly approved spinning off the company’s early clinical assets and drug discovery branch into a new company. The move keeps Johnson & Johnson (NYSE:JNJ) $30 billion takeover on track to close in the 2nd quarter.

The newly formed biopharmaceutical company will be called Idorsia Ltd and led by Actelion CEO Jean-Paul Clozel. Shares in Idorsia are expected to list on the SIX Swiss Exchange on the day that Johnson & Johnson’s tender offer closes.

J&J will initially hold 16% of Idorsia shares, the U.S. healthcare giant said. It plans to de-list Actelion.

“After a very successful 2 decades, resulting in an unprecedented share price increase of more than 2,000% since our IPO, the next chapter for Actelion awaits,” chairman Jean-Pierre Garnier said, according to Reuters. “With the successful tender offer by Johnson & Johnson, regulatory approvals on track, and today’s approval by the shareholders to spin out Idorsia, the transaction is moving ahead at full steam.”

Last month, Johnson & Johnson said that it controls nearly 78% of voting rights in its acquisition of Actelion. Janssen, J&J’s Swiss subsidiary, declared the tender offer successful.

J&J will have 10 more trading days, between April 6 and April 21, for the subsequent acceptance of the tender offer, according to the company.

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS